David M.

Koelle

MD

related links

bio

Dr. Koelle’s research concerns harnessing the power of the immune system to prevent and fight infectious agents and infection-related cancer.  The main emphasis in the lab is on chronic viral agents such as HSV-1, HSV-2, and VZV, but a variety of other microbes are of interest.  Pathogen-specific T cells are the focus, but study of innate and specific antibody responses is often incorporated. Spanning infections, the lab tries to understand the intricacies of T cell recognition and control of invaders, including T cell receptor and HLA immunogenetics and receptor diversity, antigenic regions of pathogen proteins, T cell residency in tissues, and technologies to accurately measure T cell responses in vaccinated or infected subjects.
Dr. Koelle is Principle Investigator of several NIH Grants and Contracts, and collaborates widely with other Seattle-based, national, and international investigators. Current funded projects concern HSV-1, HSV-2, VZV, Merkel cell polyomavirus, HHV-8, syphilis, and SARS-CoV-2.  The lab has shepherded HSV vaccine candidates through the discovery, animal model, and clinical trial phases.  In addition to externally funded research, Dr. Koelle supervises clinical IGRA testing for tuberculosis within UW Medicine and chairs clinical trial evaluations for the Institutional Biosafety Committee.
His previous work includes studies of Zika virus, polio, HHV-6, rotavirus, CMV, EBV, orthopoxviruses such as monkeypox and vaccinia, HSV and CMV drug resistance, and severe drug-related adverse immune responses.
 

research interests

• Vaccines for chronic viral infections: preventative and therapeutic
• Antiviral drug development
• Immunotherapy for pathogen-related malignancies
• Local T cell responses at barrier sites: skin, respiratory tract
• T cell based diagnostics

clinical interests

• General Infectious Diseases
• Herpesvirus infections
• Adoptive cell therapy for pathogen-related cancers

education & training

BS, University of Washington (1980)

MD, University of Washington (1985)

Intern, New England Medical Center, Boston, MA (1985-1986)

Resident, New England Medical Center, Boston, MA (1986-1988)

Attending Physician, Hall Health Center, University of Washington (1988-1989)

Fellow, Division of Allergy and Infectious Diseases, University of Washington (1989-1992)
 

honors

American Society of Clinical Investigation

Fellow, Infectious Disease Society of America
 

publications

Elyanow R, Snyder TM, Dalai SC, Gittelman RM, Boonyaratanakornkit J, Wald A, Selke S, Wener MH, Morishima C, Greninger A, Gale M, Hsiang T-Y, Jing L, Holbrook MR, Kaplan IM, Zahid HJ, May DH, Carlson JM, Baldo L, Manley T, Robins HS, Koelle DM. 2022. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity.  JCI Insight 7:e150070. PMID 35439166

Laing KJ, Ouwendijk WJD, Campbell VL, McClurkan CL, Mortazavi S, Elder-Waters M, Krist M, Tu R, Nguyen N, Basu K, Mioa C, Schmid DS, Johnston C, Verjans GMGM, Koelle DM. 2022. Human skin tissue resident memory virus-specific T cells after shingles. In Press, Nature Communications   (realize you can’t link to this but please list anyway)

Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, Afanasiev OK, Colunga AG, Cook MM, Xie H, Greninger AL, Paulson KG, Chapuis AG, Bhatia S, Nghiem P, Koelle DM. 2020. High prevalence and diverse HLA restriction of intratumoral oncoprotein-specific CD8 T cells in polyoma virus-driven Merkel cell carcinoma. Cancer Immunology Research 8: 648-659. PMID 32179557. PMCID 7197523.

Jing L, Wu X, Krist MP, Campbell VL, Hsiang T-Y, McClurkan CL, Favors SM, Hemingway LA, Godornes C, Tong DQ, Selke S, LeClair AC, Pyo C-W, Geraghty DE, Laing KJ, Wald A, Gale M, Koelle DM.  2022. T cell response to intact SARS-CoV-2 includes coronavirus crossreactive and variant-specific components. JCI Insight 7(6):e158126. PMID 35133988. PMCID 8986086  

Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McCuffin S, Shapiro A, Campbell V, McClurkan CL, Jing L, Gross R, Liang J, Postnikova E, Mazur S, Lukin VV, Chaudhary A, Das MK, Fink S, Bryan A, Greninger A, Jerome KR, Holbrook M, Gernsheimer T, Wener M, Wald A, Koelle DM. 2021. Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19 disease.131:e144930. Journal of Clinical Investigation. PMID 33320842. PMCID 7843229.